True hyperprolactinemia in men without visible pituitary adenoma.
Cabergoline
MRI
Men
Prolactinoma
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
10
2020
accepted:
09
01
2021
pubmed:
11
2
2021
medline:
9
7
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Men with mild to moderate hyperprolactinemia rarely present with normal pituitary on MRI with no visible adenoma, a condition entitled also "idiopathic hyperprolactinemia" or "non-tumoral hyperprolactinemia". We have characterized a cohort of hyperprolactinemic men with normal pituitary imaging. We have identified 13 men with true hyperprolactinemia and normal pituitary MRI. Baseline clinical and hormonal characteristics and response to medical treatment were retrospectively retrieved from medical records. Mean age at diagnosis was 51 ± 16 years (range, 20-77); mean serum prolactin level at presentation was 91 ng/ml (range, 28-264), eight men presented with low baseline testosterone. Initial complaints leading to diagnosis included sexual dysfunction in ten men and gynecomastia in five. All patients were treated with cabergoline, except for one who was given bromocriptine; none required pituitary surgery. All patients normalized prolactin and testosterone with subsequent clinical improvement reported by most men. Currently, after a mean follow-up of 72 months, ten patients continue treatment with caborgoline (median weekly dose, 0.25 mg), whereas three men discontinued treatment. Men with symptomatic hyperprolactinemia may rarely present with normal pituitary imaging. Medical treatment can lead to hormonal improvement with clinical benefit.
Identifiants
pubmed: 33566310
doi: 10.1007/s12020-021-02624-1
pii: 10.1007/s12020-021-02624-1
doi:
Substances chimiques
Prolactin
9002-62-4
Cabergoline
LL60K9J05T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-813Références
M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006)
doi: 10.1210/er.2005-9998
T. Mindermann, C.B. Wilson, Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. 41, 359–364 (1994)
doi: 10.1111/j.1365-2265.1994.tb02557.x
H. Duskin-Bitan, I. Shimon, Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020)
doi: 10.1007/s11102-019-01009-y
P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019)
doi: 10.1016/j.beem.2019.101290
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Eng. J. Med. 331, 904–909 (1994)
doi: 10.1056/NEJM199410063311403
A. Colao, A.D. Sarno, P. Cappabianca, F. Briganti, R. Pivonello, C.D. Somma, A. Faggiano, B. Biondi, G. Lombardi, Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325–331 (2003)
doi: 10.1530/eje.0.1480325
A.M. Lenz, A.W. Root, Empty sella syndrome. Ped. Endocrinol. Rev. 9, 710–715 (2012)
E. Horvath, K. Kovacs, B.W. Scheithauer, Pituitary hyperplasia. Pituitary 1, 169–179 (1999)
doi: 10.1023/A:1009952930425
J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano, The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412–418 (1989)
doi: 10.1210/jcem-68-2-412
A.K. Kalsi, A. Halder, M. Jain, P.K. Chaturvedi, J.B. Sharma, Prevalence and reproductive manifestations of macroprolactinemia. Endocrine 63, 332–340 (2019)
doi: 10.1007/s12020-018-1770-6
O.M. Hauache, A.J. Rocha, A.C. Maia Jr, R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. 57, 327–331 (2002)
doi: 10.1046/j.1365-2265.2002.01586.x
A. Glezer, M.D. Bronstein, Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J. Clin. Endocrinol. Metab. 97, 2211–2216 (2012)
doi: 10.1210/jc.2011-2976
A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, G. Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704–1711 (2004)
doi: 10.1210/jc.2003-030979
A.H. Zamanipoor Najafabadi, I.M. Zandbergen, F. de Vries, L.H.A. Broersen, M.E. van den Akker-van Marle, A.M. Pereira, W.C. Peul, O.M. Dekkers, W.R. van Furth, N.R. Biermasz, Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32–e41 (2020)
doi: 10.1210/clinem/dgz144
D. Maiter, E. Delgrange, Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014)
doi: 10.1530/EJE-14-0013